News headlines about Antares Pharma (NASDAQ:ATRS) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Antares Pharma earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 44.537462989505 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Antares Pharma (NASDAQ:ATRS) opened at $2.28 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89. The company has a market capitalization of $358.79, a PE ratio of -20.73 and a beta of 0.25. Antares Pharma has a 12 month low of $1.58 and a 12 month high of $4.09.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). The business had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.01 million. Antares Pharma had a negative return on equity of 43.05% and a negative net margin of 32.06%. The firm’s revenue was up 11.9% compared to the same quarter last year. research analysts predict that Antares Pharma will post -0.11 EPS for the current fiscal year.

Several research firms have weighed in on ATRS. HC Wainwright set a $5.00 target price on Antares Pharma and gave the company a “buy” rating in a report on Friday, October 13th. Piper Jaffray Companies set a $3.00 target price on Antares Pharma and gave the company a “buy” rating in a report on Monday, October 23rd. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. Finally, ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. One analyst has rated the stock with a sell rating, four have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $3.84.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2018/01/13/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-antares-pharma-atrs-stock-price.html.

About Antares Pharma

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Insider Buying and Selling by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.